Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | TYK2 | P29597 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 8/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173680 | 0.92 | RPS6KB1 (0.45) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174524 | 0.91 | AURKA (0.44) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL161721 | 0.88 | JAK3 (0.44) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL173588 | 0.88 | AURKA (0.44) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL173868 | 0.88 | NTRK1 (0.46) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174410 | 0.88 | AURKA (0.41) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174181 | 0.87 | AURKA (0.44) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL161448 | 0.87 | AURKA (0.42) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174061 | 0.87 | AURKA (0.44) | JAK2JAK3CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL174437 | 0.86 | AURKA (0.43) | JAK2JAK3CYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | claimed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | claimed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | claimed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | JAK2 2/4885JAK3 1/4885CYP3A4 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.